A Multi-center Open-label Trial Evaluating the Efficacy and Safety of Daratumumab SC in Treatment of Patients With Proliferative Glomerulonephritis With Monoclonal Immunoglobulin Deposits (PGNMID)
Latest Information Update: 07 Jun 2025
At a glance
- Drugs Daratumumab (Primary)
- Indications Membranoproliferative glomerulonephritis
- Focus Therapeutic Use
Most Recent Events
- 03 May 2024 Planned primary completion date changed from 1 Aug 2025 to 1 Aug 2026.
- 18 Aug 2023 Planned End Date changed from 1 Mar 2026 to 1 Aug 2026.
- 18 Aug 2023 Planned primary completion date changed from 1 Mar 2025 to 1 Aug 2025.